Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | WNT3 | P56703 | 2/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9506253 | 1.00 | NR1H2 (0.50) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL12267639 | 0.91 | NR1H2 (0.50) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL13106876 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL9503295 | 0.90 | NR1H2 (0.48) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL9503339 | 0.89 | MMP1 (0.55) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL9006094 | 0.89 | STS (0.49) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL9505085 | 0.88 | NR1H2 (0.50) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL30638141 | 0.87 | MMP2 (0.52) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL12267638 | 0.85 | CA12 (0.42) | NR1H2NR1H3MMP2CA12CA1 | |
| SCHEMBL13128283 | 0.83 | MEN1 (0.48) | NR1H2NR1H3MMP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| EP-0289911-B1 | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| US-4916152-A | THROMBOXANE A2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0289911-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | NR1H2 2730/4885NR1H3 3000/4885MMP2 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.